Nicholson Nur — SEC Form 4 filings
SEC reporting owner CIK 1827317. 15 Form 4 filings on record with FilingPulse; latest filed 2026-09-09.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-01-17 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 11 filings — 38,601 shares, $1,546,100 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: sale of 7,768 shares @ $57.31 ($445,161) in Apellis Pharmaceuticals, Inc., filed 2024-03-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) | Chief Technical Officer | 14 | — | 12 legs · 38,601 sh · $1,546,100 | 24 |
| Kailera Therapeutics, Inc. (KLRA) | Chief Technology Officer | 1 | — | — | 1 |
Form 4 filings — Nicholson Nur
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Kailera Therapeutics, Inc. (KLRA) | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Code (U): 116,338 · Grant/award (A): 22,610 · Disposition to issuer (D): 22,610 · Grant/award (A): 45,220 · Disposition to issuer (D): 45,220 · Grant/award (A): 24,284 · +13 more | EDGAR |
| 2026-01-30 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 45,220 @ $0 | EDGAR |
| 2026-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 7,725 @ $21.77 | EDGAR |
| 2026-01-21 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 2,203 @ $19.79 | EDGAR |
| 2026-01-15 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 2,618 @ $22.19 | EDGAR |
| 2025-06-11 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 82,500 (derivative) @ $19.39 | EDGAR |
| 2025-01-30 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 825 @ $29.52 | EDGAR |
| 2025-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 3,948 @ $30.43 | EDGAR |
| 2025-01-21 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 2,145 @ $29.96 · Grant/award (A): 36,426 @ $0 | EDGAR |
| 2025-01-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 2,632 @ $28.70 | EDGAR |
| 2024-03-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 7,768 @ $57.31 · Sale (S): 3,452 @ $58.13 | EDGAR |
| 2024-01-31 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 835 @ $64.14 | EDGAR |
| 2024-01-23 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Sale (S): 2,593 @ $65.00 | EDGAR |
| 2024-01-17 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 19,508 @ $0 · Sale (S): 1,857 @ $66.81 · Grant/award (A): 28,367 (derivative) @ $66.30 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1827317 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →